Phathom Pharmaceuticals (PHAT)
Brings Takeda's vonoprazan acid blocker to U.S. patients under the VOQUEZNA brand.
$7.08
vs last close−0.69 (−8.83%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 89.61% | 72.49M shares | |
|---|---|---|---|
| 173 holders · as of Jun 30, 2026 | |||
| Insiders | 9.90% | 8.01M shares | |
| 14 holders · as of Sep 8, 2026 | |||
| Other | 0.49% | 399.4K shares | |
| remainder | |||
80.90M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
173 holders · 72.49M shares · 24 new positions · 85 increased · 50 reduced · 34 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 12.47M | 15.41% | 0 | Aug 14, 2026 |
| Medicxi Ventures Management (Jersey) Ltd | 7.46M | 9.23% | 0 | Aug 4, 2026 |
| BlackRock, Inc. | 4.53M | 5.59% | +463.1K | Aug 7, 2026 |
| Invesco Ltd. | 4.03M | 4.98% | −292.3K | Aug 14, 2026 |
| Carlyle Group Inc. | 3.50M | 4.32% | 0 | Aug 7, 2026 |
| Millennium Management LLC | 3.38M | 4.17% | −647.1K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 2.66M | 3.28% | +73.3K | Aug 13, 2026 |
| GW&K Investment Management, LLC | 2.17M | 2.68% | +745.7K | Aug 12, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| James N. Topperincl. Frazier Life Sciences Public Fund, L.P., Frazier Life Sciences X, L.P. +14 more | 8.60% | 5.99M | 13D | Nov 4, 2025 |
| BlackRock, Inc. | 5.50% | 4.38M | 13G | Jul 29, 2026 |
| Millennium Management LLC | 5.30% | 4.18M | 13G | Mar 12, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Nov 3, 2025 | Robert Charles Breedloveofficer: Principal Accounting Officer | Sale | 524 | $13.51 | 47,407 |
House and Senate disclosures
Not reported.